Paired boxed gene 1 expression

A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma

Li Chun Liu, Hung Cheng Lai, Yu Ching Chou, Rui Lan Huang, Mu Hsien Yu, Chi Pin Lin, Wen Chiuan Tsai, Kai Jo Chiang, Yu Chi Wang, Tai Kuang Chao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: Paired boxed gene 1 (PAX1) has previously been reported to be a methylation-silenced gene in cases of cervical and ovarian cancers. We evaluated the expression of PAX1 in normal endometrium, endometrial hyperplasia and endometrial carcinoma (EC), and investigated the prognostic value of PAX1 expression in patients with EC. Methods: We conducted a hospital-based retrospective review of PAX1 distribution immunohistochemically in 201 samples of endometrium from biopsy or hysterectomy. PAX1 immunoreactivity was classified into low and high score groups based upon the extent and intensity of staining. Results: There was intense intranuclear staining for PAX1 in premalignant endometrial lesions. A high PAX1 score was observed in a high percentage of samples of normal endometrium (93.3%), in endometrial hyperplasia without atypia (97.2%) and in endometrial atypical hyperplasia (87.5%), but this level was found in only one-third of the EC samples (30.1%). The PAX1 protein score was significantly higher in samples of premalignant endometrial lesions compared with those of EC (P < 0.001). Importantly, a higher PAX1 score in EC cases was correlated with good overall survival, with a hazard ratio of 0.22 for death (95% confidence interval, 0.05–0.96). Conclusions: PAX1 protein expression is a potential histopathology biomarker for the differential diagnosis of malignant and premalignant endometrial lesions. PAX1 is also a potential prognostic marker in cases of EC.

Original languageEnglish
Pages (from-to)1159-1167
Number of pages9
JournalJournal of Obstetrics and Gynaecology Research
Volume42
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Endometrial Neoplasms
Biomarkers
Endometrial Hyperplasia
Gene Expression
Endometrium
Staining and Labeling
Hysterectomy
Uterine Cervical Neoplasms
Ovarian Neoplasms
Methylation
Genes
Proteins
Differential Diagnosis
Confidence Intervals
Biopsy
Survival

Keywords

  • atypical endometrial hyperplasia
  • endometrial carcinoma
  • endometrial hyperplasia
  • immunohistochemistry
  • PAX1

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Cite this

Paired boxed gene 1 expression : A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. / Liu, Li Chun; Lai, Hung Cheng; Chou, Yu Ching; Huang, Rui Lan; Yu, Mu Hsien; Lin, Chi Pin; Tsai, Wen Chiuan; Chiang, Kai Jo; Wang, Yu Chi; Chao, Tai Kuang.

In: Journal of Obstetrics and Gynaecology Research, Vol. 42, No. 9, 01.09.2016, p. 1159-1167.

Research output: Contribution to journalArticle

Liu, Li Chun ; Lai, Hung Cheng ; Chou, Yu Ching ; Huang, Rui Lan ; Yu, Mu Hsien ; Lin, Chi Pin ; Tsai, Wen Chiuan ; Chiang, Kai Jo ; Wang, Yu Chi ; Chao, Tai Kuang. / Paired boxed gene 1 expression : A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. In: Journal of Obstetrics and Gynaecology Research. 2016 ; Vol. 42, No. 9. pp. 1159-1167.
@article{8cc570d097b74a96835f2cb5cde446d0,
title = "Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma",
abstract = "Aim: Paired boxed gene 1 (PAX1) has previously been reported to be a methylation-silenced gene in cases of cervical and ovarian cancers. We evaluated the expression of PAX1 in normal endometrium, endometrial hyperplasia and endometrial carcinoma (EC), and investigated the prognostic value of PAX1 expression in patients with EC. Methods: We conducted a hospital-based retrospective review of PAX1 distribution immunohistochemically in 201 samples of endometrium from biopsy or hysterectomy. PAX1 immunoreactivity was classified into low and high score groups based upon the extent and intensity of staining. Results: There was intense intranuclear staining for PAX1 in premalignant endometrial lesions. A high PAX1 score was observed in a high percentage of samples of normal endometrium (93.3{\%}), in endometrial hyperplasia without atypia (97.2{\%}) and in endometrial atypical hyperplasia (87.5{\%}), but this level was found in only one-third of the EC samples (30.1{\%}). The PAX1 protein score was significantly higher in samples of premalignant endometrial lesions compared with those of EC (P < 0.001). Importantly, a higher PAX1 score in EC cases was correlated with good overall survival, with a hazard ratio of 0.22 for death (95{\%} confidence interval, 0.05–0.96). Conclusions: PAX1 protein expression is a potential histopathology biomarker for the differential diagnosis of malignant and premalignant endometrial lesions. PAX1 is also a potential prognostic marker in cases of EC.",
keywords = "atypical endometrial hyperplasia, endometrial carcinoma, endometrial hyperplasia, immunohistochemistry, PAX1",
author = "Liu, {Li Chun} and Lai, {Hung Cheng} and Chou, {Yu Ching} and Huang, {Rui Lan} and Yu, {Mu Hsien} and Lin, {Chi Pin} and Tsai, {Wen Chiuan} and Chiang, {Kai Jo} and Wang, {Yu Chi} and Chao, {Tai Kuang}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/jog.13040",
language = "English",
volume = "42",
pages = "1159--1167",
journal = "Journal of Obstetrics and Gynaecology Research",
issn = "1341-8076",
publisher = "Wiley/Blackwell (10.1111)",
number = "9",

}

TY - JOUR

T1 - Paired boxed gene 1 expression

T2 - A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma

AU - Liu, Li Chun

AU - Lai, Hung Cheng

AU - Chou, Yu Ching

AU - Huang, Rui Lan

AU - Yu, Mu Hsien

AU - Lin, Chi Pin

AU - Tsai, Wen Chiuan

AU - Chiang, Kai Jo

AU - Wang, Yu Chi

AU - Chao, Tai Kuang

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim: Paired boxed gene 1 (PAX1) has previously been reported to be a methylation-silenced gene in cases of cervical and ovarian cancers. We evaluated the expression of PAX1 in normal endometrium, endometrial hyperplasia and endometrial carcinoma (EC), and investigated the prognostic value of PAX1 expression in patients with EC. Methods: We conducted a hospital-based retrospective review of PAX1 distribution immunohistochemically in 201 samples of endometrium from biopsy or hysterectomy. PAX1 immunoreactivity was classified into low and high score groups based upon the extent and intensity of staining. Results: There was intense intranuclear staining for PAX1 in premalignant endometrial lesions. A high PAX1 score was observed in a high percentage of samples of normal endometrium (93.3%), in endometrial hyperplasia without atypia (97.2%) and in endometrial atypical hyperplasia (87.5%), but this level was found in only one-third of the EC samples (30.1%). The PAX1 protein score was significantly higher in samples of premalignant endometrial lesions compared with those of EC (P < 0.001). Importantly, a higher PAX1 score in EC cases was correlated with good overall survival, with a hazard ratio of 0.22 for death (95% confidence interval, 0.05–0.96). Conclusions: PAX1 protein expression is a potential histopathology biomarker for the differential diagnosis of malignant and premalignant endometrial lesions. PAX1 is also a potential prognostic marker in cases of EC.

AB - Aim: Paired boxed gene 1 (PAX1) has previously been reported to be a methylation-silenced gene in cases of cervical and ovarian cancers. We evaluated the expression of PAX1 in normal endometrium, endometrial hyperplasia and endometrial carcinoma (EC), and investigated the prognostic value of PAX1 expression in patients with EC. Methods: We conducted a hospital-based retrospective review of PAX1 distribution immunohistochemically in 201 samples of endometrium from biopsy or hysterectomy. PAX1 immunoreactivity was classified into low and high score groups based upon the extent and intensity of staining. Results: There was intense intranuclear staining for PAX1 in premalignant endometrial lesions. A high PAX1 score was observed in a high percentage of samples of normal endometrium (93.3%), in endometrial hyperplasia without atypia (97.2%) and in endometrial atypical hyperplasia (87.5%), but this level was found in only one-third of the EC samples (30.1%). The PAX1 protein score was significantly higher in samples of premalignant endometrial lesions compared with those of EC (P < 0.001). Importantly, a higher PAX1 score in EC cases was correlated with good overall survival, with a hazard ratio of 0.22 for death (95% confidence interval, 0.05–0.96). Conclusions: PAX1 protein expression is a potential histopathology biomarker for the differential diagnosis of malignant and premalignant endometrial lesions. PAX1 is also a potential prognostic marker in cases of EC.

KW - atypical endometrial hyperplasia

KW - endometrial carcinoma

KW - endometrial hyperplasia

KW - immunohistochemistry

KW - PAX1

UR - http://www.scopus.com/inward/record.url?scp=84985946074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985946074&partnerID=8YFLogxK

U2 - 10.1111/jog.13040

DO - 10.1111/jog.13040

M3 - Article

VL - 42

SP - 1159

EP - 1167

JO - Journal of Obstetrics and Gynaecology Research

JF - Journal of Obstetrics and Gynaecology Research

SN - 1341-8076

IS - 9

ER -